DelveInsight’s, “Parkinson’s Disease Pipeline Insight, 2022,” report provides comprehensive insights about 140+ companies and 150+ pipeline drugs in Parkinson’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Parkinson’s Disease Pipeline Insight Report

• DelveInsight’s Parkinson’s disease Pipeline report depicts a robust space with 140+ active players working to develop 150+ pipeline therapies for Parkinson’s disease.
• The leading Parkinson’s Disease Companies such as Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics,Cerevance, Aspen Neuroscience,Prilenia Therapeutics,Cortexyme Inc.,Gain Therapeutics, Clexio Biosciences,  Orpheris, Inc., Alkahest, Inc.,  and others are developing potential drug candidates to improve the Parkinson’s Disease treatment scenario.
• Promising Parkinson’s Disease Pipeline therapies such as LY03003, Istradefylline 20 mg, LY3884961, Methylprednisolone, Sirolimus, VY-AADC02, Liatermin, MEDI1341, Levodopa-Carbidopa, and others are under different phases of Parkinson’s Disease clinical trials.
• In the coming years, the Parkinson’s disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Parkinson’s disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

 

Get an overview of the Parkinson’s disease Pipeline landscape @ Parkinson’s disease Emerging Therapies

 

Parkinson’s disease overview

Parkinson’s disease is a progressive disorder that is caused by degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important chemical called dopamine. Studies have shown that symptoms of Parkinson’s develop in patients with an 80 percent or greater loss of dopamine-producing cells in the substantia nigra. Normally, dopamine operates in a delicate balance with other neurotransmitters to help coordinate the millions of nerve and muscle cells involved in movement. Without enough dopamine, this balance is disrupted, resulting in tremor (trembling in the hands, arms, legs and jaw); rigidity (stiffness of the limbs); slowness of movement; and impaired balance and coordination – the hallmark symptoms of Parkinson’s. The cause of Parkinson’s essentially remains unknown.

 

Latest Breakthroughs of Parkinson’s disease Treatment Landscape

• In December 2021, Pharma Two B Ltd., announced that its Phase III double-blind, active-controlled study of P2B001 in early Parkinson’s disease successfully met its primary and key secondary endpoints in the Phase III study, P2B001 was superior to each of its individual components as measured by the change from baseline to week 12 in total Unified Parkinson’s Disease Rating Scale (UPDRS Part II and III; primary endpoint). P2B001 was superior to the pramipexole component by 2.66 points (p=0.0018) and superior to the rasagiline component by 3.30 points (p=0.0001).
• In December 2021, UCB announced that it has entered into a global co-development and co-commercialization agreement with Novartis covering UCB0599, a potential first in class, small molecule, alpha-synuclein misfolding inhibitor currently in Phase 2 clinical development, and upon completion of the ongoing Phase 1 program, an opt-in to co-develop UCB7853, an anti-alpha-synuclein antibody, both in Parkinson’s Disease (PD).
• Gain Therapeutics presented preclinical data during a poster session at the Society for Neuroscience Annual Meeting, being held virtually from November 8 – 11, 2021. The findings demonstrate that the Company’s lead compound GT-02287, which specifically binds to lysosomal enzyme glucocerebrosidase (GCase), reduces alpha-synuclein pathology and neuroinflammation in a dose-dependent manner, as well as improves behavioral deficits in an animal model of Parkinson’s Disease.
• In November 2021, Sio Gene Therapies Inc. provided a manufacturing and regulatory update for AXO-Lenti-PD, its clinical-stage gene therapy for Parkinson’s disease. Three GMP batches successfully completed fill and finish, achieving target titers using the updated suspension-based process
• In October 2021, AbbVie announced that continuous 24 hours/day subcutaneous infusion of ABBV-951 (foslevodopa/foscarbidopa) was statistically superior to oral levodopa/carbidopa in reducing motor fluctuations in patients with advanced Parkinson’s disease (PD) in a Phase 3, randomized, double-blind, double-dummy, active-controlled study. The study met its primary endpoint of increase from baseline in “On” time (hours) without troublesome dyskinesia (involuntary movements) after 12 weeks based on the Parkinson’s Disease Diary (PD Diary). These results will be a key component of global regulatory submissions.
• In October 2021, Inhibikase Therapeutics announced the dosing of the first Parkinson’s patient in its Phase 1b clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, an inhibitor for the treatment of Parkinson’s disease.
• In May 2021, Denali Therapeutics announced final results from Phase 1 and Phase 1b studies of its small molecule LRRK2 inhibitor, BIIB122/DNL151, which is being developed in collaboration with Biogen as a potential treatment of Parkinson’s disease.
• In April 2021, Cerevel Therapeutics announced an up to $125 million non-dilutive financing transaction with NovaQuest and Bain Capital to fund the full Phase 3 development program for tavapadon in Parkinson’s disease, also known as the TEMPO trials.

 

Get an overview of Parkinson’s disease Pipeline landscape @ Parkinson’s Disease Clinical Trials Analysis

 

 

Parkinson’s Disease Emerging Drugs

• Tavapadon: Cerevel Therapeutics
• IkT-148009: Inhibikase Therapeutics
• NLY01: Neuraly
• PT320: Peptron

 

DelveInsight’s Parkinson’s Disease Pipeline Report covers around 150+ products under different phases of clinical development like-

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

For further information, refer to the detailed report @ Parkinson’s Disease Pipeline Therapeutics

 

 

Scope of Parkinson’s Disease Pipeline Drug Insight 

• Coverage: Global 
• Parkinson’s Disease Phases- Late stage products (Phase III), Mid-stage products (Phase II), Early-stage product (Phase I) along with the details of, Pre-clinical and Discovery stage candidates, Discontinued & Inactive candidates
• Prominent Parkinson’s Disease Companies: Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics, Cerevance, Aspen Neuroscience, Prilenia Therapeutics, Cortexyme Inc., Gain Therapeutics, Clexio Biosciences,  Orpheris, Inc., Alkahest, Inc., and many others.
• Parkinson’s Disease Pipeline Therapies-LY03003, Istradefylline 20 mg, LY3884961, Methylprednisolone, Sirolimus, VY-AADC02, Liatermin, MEDI1341, Levodopa-Carbidopa, and others are under different phases of Parkinson’s Disease clinical trials
• Parkinson’s Disease- Market Drivers and Barriers

 

Dive deep into rich insights for new drugs for Parkinson’s Disease treatment, visit @ Parkinson’s Disease Drugs

 

Table of Content

1. Introduction
2. Executive Summary
3. Parkinson’s Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Parkinson’s Disease – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Tavapadon: Cerevel Therapeutics
9. Mid Stage Products (Phase II)
10. Prasinezumab : Roche
11. Early Stage Products (Phase I)
12. MEDI1341: AstraZeneca
13. Preclinical and Discovery Stage Products
14. Neural microtissues: Treefrog Therapeutics
15. Inactive Products
16. Parkinson’s Disease Key Companies
17. Parkinson’s Disease Key Products
18. Parkinson’s Disease- Unmet Needs
19. Parkinson’s Disease- Market Drivers and Barriers
20. Parkinson’s Disease- Future Perspectives and Conclusion
21. Parkinson’s Disease Analyst Views
22. Parkinson’s Disease Key Companies
23. Appendix

 

For further information on the Parkinson’s Disease pipeline therapeutics, reach out @ Parkinson’s Disease Treatment Drugs

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/